C
Caribou Biosciences, Inc. (CRBU)
1.78
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
1.78
0.00 (0.00%)
Caribou Biosciences, Inc. klinik bosqichdagi klasterli muntazam joylashtirilgan qisqa palindromik takrorlar (CRISPR) genom muharrirlash biopharmaceutical kompaniyasi sifatida ishlaydi. U yangi CRISPR gibrid RNT-DNK genom muharrirlash texnologiyasiga asoslangan genom muharrirlash platformasini taklif etadi, bu esa allogen hujayra terapiyalarining aniq genom muharrirlashini ta'minlaydi. Kompaniya Vispacabtagene Regedleucel kompaniyasini ishlab chiqmoqda, bu esa qaytalangan yoki refrakter B-hujayrali non-Hodgkin limfomasini davolash uchun 1-fazali klinik sinovda bo'lgan allogen anti-CD19 CAR-T hujayra terapiyasi; va CB-011, qaytalangan yoki refrakter ko'p miyelomani davolash uchun 1-fazali klinik sinovda bo'lgan allogen anti-BCMA CAR-T hujayra terapiyasi. Caribou Biosciences, Inc. 2011 yilda tashkil etilgan va uning shtab-kvartirasi Kaliforniyaning Berkeley shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, President & Director |
| Dr. Tina Albertson M.D., Ph.D. | Chief Medical Officer |
| Mr. Ryan Fischesser | Interim Principal Accounting Officer & Controller |
| Mr. Sriram Ryali M.B.A. | Chief Financial Officer |
| Mr. Timothy P. Kelly M.B.A. | Chief Technology Officer |
| Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Reigin Zawadzki | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-05 | 8-K | crbu-20260305.htm |
| 2025-11-12 | 10-Q | crbu-20250930.htm |
| 2025-11-03 | 8-K | crbu-20251103.htm |
| 2025-08-12 | 8-K | crbu-20250812.htm |
| 2025-06-23 | 8-K | crbu-20250618.htm |
| 2025-06-13 | 8-K | crbu-20250612.htm |
| 2025-05-13 | CORRESP | filename1.htm |
| 2025-05-08 | DEFA14A | crbu-20250508proxydefa14a.htm |
| 2025-04-25 | DEFA14A | cariboubiosciencesinc_vx.htm |
| 2025-04-24 | 8-K | crbu-20250424.htm |
| Ms. Ruhi A. Khan M.B.A. |
| Chief Business Officer |